Filter Results:
(1,245)
Show Results For
- All HBS Web
(1,245)
- People (5)
- News (171)
- Research (928)
- Events (6)
- Multimedia (12)
- Faculty Publications (757)
Show Results For
- All HBS Web
(1,245)
- People (5)
- News (171)
- Research (928)
- Events (6)
- Multimedia (12)
- Faculty Publications (757)
- 22 Oct 2013
- First Look
First Look: October 22
expenditures on teammates lead to better performance in both sports teams in Canada and pharmaceutical sales teams in Belgium. These results suggest that a minor adjustment to employee bonuses-shifting the focus from the self to... View Details
Keywords: Sean Silverthorne
- Web
Souvenirs & Novelties - The Art of American Advertising
distribute them and local retailers to print their names on them at no cost. James C. Ayer, involved in the pharmaceutical industry, reaped enormous publicity benefits from the distribution of yearly almanacs. Ayer eventually established... View Details
- 14 May 2014
- News
(Re)moving the Needle
that of his father, who was trained as an engineer and ended up in the pharmaceutical industry. He holds MSc and PhD degrees in mechanical engineering from ETH Zurich and MIT, respectively, and he spent a year pursuing advanced studies in... View Details
- January 2024
- Supplement
Accounting Red Flags or Red Herrings at Catalent? (B)
By: Joseph Pacelli, ZeSean Ali and Tom Quinn
GlassHouse Research identified accounting red flags at Catalent. Fiat Lux Partners countered most of GlassHouse’s claims. Who was right? This update explores the aftermath of the short seller duel. View Details
Keywords: Accounting Audits; Acquisition; Budgets and Budgeting; Business Earnings; Earnings Management; Cost Accounting; Fair Value Accounting; Financial Reporting; Revenue Recognition; Integrated Corporate Reporting; Fairness; Moral Sensibility; Values and Beliefs; Government Legislation; Conflict of Interests; Announcements; Blogs; Debates; Lawsuits and Litigation; Stocks; Performance Productivity; Pharmaceutical Industry; Pharmaceutical Industry; United States
Pacelli, Joseph, ZeSean Ali, and Tom Quinn. "Accounting Red Flags or Red Herrings at Catalent? (B)." Harvard Business School Supplement 124-055, January 2024.
- March 2023
- Case
Moderna
By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer, Kerry Herman, Allison J. Wigen and Dave Habeeb
This multimedia case follows the story of Moderna and its entry into vaccine development in the wake of the COVID-19 pandemic. In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19.... View Details
- March 2022
- Teaching Note
Digital Manufacturing at Amgen
By: Shane Greenstein, Kyle R. Myers and Sarah Mehta
This teaching note provides guidance for instructors teaching “Digital Manufacturing at Amgen,” case no. 621-008. View Details
Keywords: Change; Change Management; Decision Making; Cost vs Benefits; Decisions; Information Technology; Analytics and Data Science; Innovation and Invention; Innovation and Management; Innovation Leadership; Innovation Strategy; Technological Innovation; Jobs and Positions; Knowledge; Leadership; Organizational Culture; Science; Strategy; Technology Adoption; Pharmaceutical Industry; Pharmaceutical Industry; United States; California; Puerto Rico; Rhode Island
- February 2021
- Case
Digital Manufacturing at Amgen
By: Shane Greenstein, Kyle R. Myers and Sarah Mehta
This case discusses efforts made by biotechnology (biotech) company Amgen to introduce digital technologies into its manufacturing processes. Doing so is complicated by the fact that the process for manufacturing biologics—or therapeutics made from living cells—is... View Details
Keywords: Digital Technologies; Change; Change Management; Decision Making; Cost vs Benefits; Decisions; Information; Analytics and Data Science; Innovation and Invention; Innovation and Management; Innovation Leadership; Innovation Strategy; Technological Innovation; Jobs and Positions; Knowledge; Leadership; Organizational Culture; Science; Strategy; Information Technology; Technology Adoption; Pharmaceutical Industry; Pharmaceutical Industry; United States; California; Puerto Rico; Rhode Island
Greenstein, Shane, Kyle R. Myers, and Sarah Mehta. "Digital Manufacturing at Amgen." Harvard Business School Case 621-008, February 2021.
- November 2020
- Supplement
Valuing Celgene's CVR
By: Benjamin C. Esty and Daniel Fisher
When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage... View Details
- January 2018
- Teaching Note
BeiGene
By: Willy Shih and Jimmy Zhang
Teaching Note for HBS No. 618-033. View Details
- June 2014
- Supplement
Merrimack Pharmaceuticals, Inc. (B)
By: Amy C. Edmondson, Bethany Gerstein and Melissa Valentine
In 2006, the leadership team at Merrimack Pharmaceuticals, Inc. had to decide whether to keep its R&D organization in functional departments or restructure it into interdisciplinary teams. This case follows the outcomes of this decision from 2006 to mid-2014, and... View Details
Keywords: Organizational Design; Groups and Teams; Collaborative Innovation and Invention; Research and Development; Pharmaceutical Industry; Pharmaceutical Industry
Edmondson, Amy C., Bethany Gerstein, and Melissa Valentine. "Merrimack Pharmaceuticals, Inc. (B)." Harvard Business School Supplement 614-083, June 2014.
- January 2014 (Revised June 2015)
- Teaching Note
Amgen Inc: Pursuing Innovation and Imitation? (A), (B)
By: Ian Mackenzie
- May 2013 (Revised October 2014)
- Case
Novartis: Leading a Global Enterprise
By: William W. George, Krishna G. Palepu and Carin-Isabel Knoop
Novartis, the world's leading healthcare company, was formed in 1996 out of a merger of two very different, mid-tier Switzerland-based pharma companies. The case traces the company's evolution over the past 17 years, as it transformed into a truly global enterprise... View Details
Keywords: Multinational Firms and Management; Talent and Talent Management; Organizational Structure; Organizational Culture; Success; Globalized Markets and Industries; Management Teams; Change Management; Business History; Mergers and Acquisitions; Global Strategy; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland
George, William W., Krishna G. Palepu, and Carin-Isabel Knoop. "Novartis: Leading a Global Enterprise." Harvard Business School Case 413-096, May 2013. (Revised October 2014.)
- February 2010 (Revised April 2010)
- Case
Organization and Strategy at Millennium (A)
By: Julie M. Wulf and Scott Waggoner
This case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder and CEO Mark... View Details
Keywords: Transformation; Leading Change; Management Succession; Organizational Change and Adaptation; Competitive Strategy; Competitive Advantage; Pharmaceutical Industry; Pharmaceutical Industry
Wulf, Julie M., and Scott Waggoner. "Organization and Strategy at Millennium (A)." Harvard Business School Case 710-415, February 2010. (Revised April 2010.)
- January 2009
- Teaching Note
Biocon: Launching a New Cancer Drug in India (TN)
By: Sunil Gupta and Das Narayandas
Teaching Note for [508026]. View Details
- August 2007 (Revised November 2008)
- Case
Biocon: Launching a New Cancer Drug in India
By: Sunil Gupta and Das Narayandas
Kiran Majumdar-Shaw, the CEO of Biocon has to make product launch timing, pricing, channel, and communications mix decisions relating to the launch of BioMAb, a new cancer drug in India. View Details
Keywords: Price; Health Care and Treatment; Marketing Strategy; Product Launch; Planning; Pharmaceutical Industry; Pharmaceutical Industry; India
Gupta, Sunil, and Das Narayandas. "Biocon: Launching a New Cancer Drug in India." Harvard Business School Case 508-026, August 2007. (Revised November 2008.)
- March 2006
- Teaching Note
Stan Lapidus: Profile of a Medical Entrepreneur (TN)
By: Robert F. Higgins, Richard G. Hamermesh and Erin Seefeld
Teaching Note to (805-087). View Details
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (B)
By: Sandra J. Sucher and Stacy McManus
When Dr. Daniel Vasella learned of the early Phase 1 trial results, he immediately decided what course of action Novartis would take. Students will be able to examine and assess the concrete steps, and the rationale behind them, that Novartis took in response to this... View Details
Keywords: Decision Making; Moral Sensibility; Innovation and Invention; Distribution; Product Development; Production; Problems and Challenges; Research and Development; Pharmaceutical Industry; Pharmaceutical Industry
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (B)." Harvard Business School Case 603-044, April 2003. (Revised October 2004.)
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (A)
By: Sandra J. Sucher and Stacy McManus
Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the... View Details
Keywords: Decision Making; Health Testing and Trials; Innovation and Invention; Markets; Distribution; Product Development; Production; Problems and Challenges; Research; Research and Development; Complexity; Pharmaceutical Industry; Pharmaceutical Industry
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (A)." Harvard Business School Case 603-043, April 2003. (Revised October 2004.)
- December 2002
- Teaching Note
Abgenix and the XenoMouse (TN)
Teaching Note for (501-061). View Details